CAPRISA 004 Tenofovir Microbicide Trial: No Impact of Tenofovir Gel on the HIV Transmission Bottleneck

Ziyaad Valley‐Omar, Sengeziwe Sibeko, Jeffrey A. Anderson, Sarah Goodier, Lise Werner, Leslie Arney, Vivek Naranbhai, Florette K. Treurnicht, Melissa-Rose Abrahams, Gama Bandawe,

The Journal of Infectious Diseases · 2012 · 16 citations · 15 references

DOIFull text

Open access

Concepts

Abstract

Alterations of the genital mucosal barrier may influence the number of viruses transmitted from a human immunodeficiency virus-infected source host to the newly infected individual. We used heteroduplex tracking assay and single-genome sequencing to investigate the effect of a tenofovir-based microbicide gel on the transmission bottleneck in women who seroconverted during the CAPRISA 004 microbicide trial. Seventy-seven percent (17 of 22; 95% confidence interval [CI], 56%-90%) of women in the tenofovir gel arm were infected with a single virus compared with 92% (13 of 14; 95% CI, 67%->99%) in the placebo arm (P = .37). Tenofovir gel had no discernable impact on the transmission bottleneck.

References

15